Therapeutic Drug Monitoring of Secukinumab in Psoriasis Patients.

Psoriasis Vulgaris Clinical Trial

— BIOLOPTIM-SEC  

Official title:

Evaluation of the Predictive Value of Early Serum Trough Concentrations and Anti-drug Antibodies of Secukinumab and the Development of a Concentration Response Curve of Secukinumab for Psoriasis Patients.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04080661
• Other study ID #: BIOLOPTIM-SEC
• Status: Completed
• Phase: Phase 4
• Start date: March 22, 2018
• Est. completion date: December 31, 2023

Study information

• Verified date: January 2024
• Source: University Hospital, Ghent
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Biologics such as secukinumab are currently the most effective treatment option for patients with moderate to severe psoriasis. But they are costly for healthcare systems and still described according to a'one dose fits all' dosing regimen, leading to potential over-and undertreatment. In this study we aim to investigate the predictive value of early serum trough levels of secukinumab and determine the therapeutic window of secukinumab in psoriasis patients.

Description:

Patients will be included after signing informed consent. After inclusion, patients will continue on standard dosing schedule of secukinumab (i.e. subcutaneous injections once a week for 5 weeks (300 mg) followed by subcutaneous injections every 4 weeks). During each study visit blood will be taken in order to quantify Ctroughs and/or anti-drug antibodies towards secukinumab. In addition, Psoriasis Area and Severity Index (PASI) and Investigator's Global Assessment (IGA) score will be evaluated by a physician. Patients complete the Dermatology Life Quality Index (DLQI) and European quality of life EQ-5D instrument at each visit.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 82
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Participants must have a clinical or histological diagnosis of chronic plaque-type psoriasis

2. Participants must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study

Exclusion Criteria:

1. Participants who have currently a predominant nonplaque form of psoriasis

2. Participants who are pregnant, nursing or planning a pregnancy

3. Participants who are unable or unwilling to undergo multiple venapunctures

4. Participants who are treated according to a different dosing schedule than standard dosing of secukinumab

Related Conditions & MeSH terms

• Psoriasis
• Psoriasis Vulgaris

Intervention

Procedure:
• Venapuncture
Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of secukinumab.

Other:
• Patient questionnaires
The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.

Locations

Country	Name	City	State
Belgium	AZ Sint-Jan	Brugge	West-Flanders
Belgium	AZ Maria Middelares	Ghent	East-Flanders
Belgium	AZ Sint-Lucas	Ghent	East-Flanders
Belgium	University Hospital Ghent	Ghent	East-Flanders
Belgium	University Hospital Leuven	Leuven	Vlaams-Brabant
Belgium	Private practice Dermatology	Maldegem	East-Flanders
Belgium	AZ Delta Rembert	Torhout	West-Flanders

Sponsors (3)

Lead Sponsor	Collaborator
University Hospital, Ghent	KU Leuven, University Ghent

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Predictive value of early serum trough concentrations of secukinumab	Prediction of the clinical response (PASI) at week 12 and/or week 24 based on serum trough concentrations of secukinumab measurements taken from week 0,1,2,3 and/or 4.	Week 0 until week 24 of treatment
Primary	Predictive value of early anti-drug antibodies of secukinumab	Prediction of the clinical response (PASI) at week 12 and/or week 24 based on anti-drug antibodies (ADA) measurements taken from week 0,1,2,3 and/or 4.	Week 0 until week 24 of treatment
Primary	Development of the therapeutic window of secukinumab in psoriasis	Defining a therapeutic window for secukinumab based on serum trough concentrations corresponding with adequate clinical response	Week 0 until week 52 of treatment
Secondary	DLQI	The DLQI (Dermatology Life Quality Index) (range 0-30) is a dermatology specific quality of life (QoL) instrument designed to assess the impact of the disease on participant's QoL. It is a ten item questionnaire that, in addition to evaluated overall QoL, can be used to assess six different aspects that may affect QoL: 1) symptoms and feelings, 2) daily activities, 3) leasure, 4) work or school performances, 5) personal relationships, and 6) treatment.; The scoring of each question is as follows: Very much - scored 3; A lot - scored 2; A little - scored 1; Not at all - scored 0; Not relevant - scored 0; Question 7, 'prevented work or studying' - scored 3. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.	Week 0 until week 52 of treatment
Secondary	EQ-5D-5L	The EQ-5D-5L comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits of the five dimensions can be combined into a 5- digit number that describes the patients' health state.	Week 0 until week 52 of treatment
Secondary	EQ VAS	The EQ VAS (Visual Analogue Scale) (range 0-10) records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.	Week 0 until week 52 of treatment